{
  "index": 642,
  "prompt": "\nGiven the following scenario, first consider the actors and stakeholders involved then extrapolate and present as a timeline how the situation might evolve. \nConsider as many multiple possibilities based on possible responses which are to be represented as branches on this timeline. \n\nMake sure that the timeline generated are of **HIGH QUALITY** as defined by the following criteria\n* Plausibility: Economic, financial and political plausibility of each path on the timeline \n    * High: Events are strongly supported by current macro data, institutional knowledge, and have strong analogs in history or system models (e.g., “monetary tightening leads to recession, triggering a political backlash”)\n    * Low: Contains major violations of cause-effect logic, timing, or real-world behavior (e.g., hyperinflation causes interest rate cuts during a currency collapse)\n* Novelty: Creativity/originality in the nodes and paths, are they something you may have overlooked?\n    * High: Demonstrates expert-level creative reasoning. Identifies counterintuitive paths, rare risks, or hidden feedback loops. May challenge conventional wisdom in a grounded way (e.g., “trade war accelerates global realignment of semiconductors via Middle East sovereign wealth capital”). Could lead to edge in investment or policy thinking.\n    * Low: Timeline is linear, obvious, or closely tracks past headlines or boilerplate analysis. No creative branching or exploration.\n* Elaboration: How specific and refined are the occurrences represented by the nodes?\n    * High: Timeline reads like a mini-case study. Each node could stand alone as an actionable insight. Paths show feedback loops, strategic responses, and sector-level granularity (e.g., “Volkswagen reallocates $1.2B R&D from EVs to hybrid tech in response to rare earth prices”). Truly investment-grade thinking.\n    * Low: Nodes are generic (e.g., “market reacts”, “tensions rise”) with no detail on mechanisms, actors, or consequences. Lacks causal clarity.\n* Actionable: Can this timeline inform specific investment actions or hedging strategies?\n    * High: Timeline includes sector impacts, asset class consequences, or opportunities (e.g., “short EU auto suppliers”, “long U.S. rail freight”)\n    * Low: Insightful narrative, but no clear link to tradable instruments or positioning ideas\n\nKeep to the output format below where ascii is used to represent the timeline as a tree. \n\n[Example of Scenario]\nWASHINGTON/DETROIT, April 29 (Reuters) - U.S. President Donald Trump signed a pair of orders to soften the blow of his auto tariffs on Tuesday with a mix of credits and relief from other levies on materials, and his trade team touted its first deal with a foreign trading partner.\nThe developments helped eased some investor worries about the erratic trade policies of Trump as the president visited Michigan, a cradle of the U.S. auto industry, just days before a fresh set of 25% import taxes was set to kick in on automotive components.\n\n[Example of Output]\n{\n  \"id\": \"T0\",\n  \"title\": \"Initial Event\",\n  \"description\": \"German inflation data released at 2.2%\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"ECB maintains dovish stance\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB maintains dovish stance, keeps rates low\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"German banks increase lending\",\n          \"description\": \"German banks benefit from low rates, increase lending\"\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Euro weakens\",\n          \"description\": \"Euro weakens, boosting exports\"\n        },\n        {\n          \"id\": \"T1A1.3\",\n          \"title\": \"Moderate industrial growth\",\n          \"description\": \"German industry reports moderate growth\"\n        },\n        {\n          \"id\": \"T1A1.4\",\n          \"title\": \"Bundesbank caution\",\n          \"description\": \"Bundesbank signals caution on inflation\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Industry adapts to inflation\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Companies pass on higher costs; unions request wage hikes; consumer shifts emerge\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Markets stabilize\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Eurozone growth outlook improves; German stocks outperform\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Global growth stabilizes\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Global trade rebounds; emerging markets benefit\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"New normal\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Stable growth across EU/US; ECB remains dovish\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"ECB tightens monetary policy\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB tightens policy in response to inflation\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Euro strengthens\",\n          \"description\": \"Euro strengthens, hurting exports\"\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Industrial slowdown\",\n          \"description\": \"German industry reports slower growth\"\n        },\n        {\n          \"id\": \"T1A2.3\",\n          \"title\": \"Bundesbank warns\",\n          \"description\": \"Bundesbank warns of inflation risks\"\n        },\n        {\n          \"id\": \"T1A2.4\",\n          \"title\": \"Consumers cut back\",\n          \"description\": \"German consumers cut back on spending\",\n          \"children\": [\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Industry opposes ECB policy\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Job cuts, political backlash, delayed consumption\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"Markets unstable\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Growth outlook declines; ECB remains hawkish\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Global recession risk rises\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Trade slows; emerging markets struggle\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Global downturn\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Recession conditions persist; ECB maintains rate hikes\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n\n[Given Scenario]\nThe global immunotoxins market size was estimated at USD 142.2 million in 2023 and is projected to reach USD 344.7 million by 2034, reflecting a compound annual growth rate (CAGR) of 8.11% during the forecast period of 2024 to 2034. This growth is attributed to the rising global prevalence of various malignancies, increased research and development (R&D) activities, heightened investment and funding, the approval of new immunotoxin therapies, and an increase in collaborations and partnerships.\n\nBy product, the Diphtheria Toxin (DT) segment emerged as the highest revenue-generating segment in the global immunotoxins market in 2023, due to the proven effectiveness of DT-based immunotoxins in targeted cancer therapies. The Pseudomonas Exotoxin segment is anticipated to witness the fastest CAGR during the forecast period, driven by the success of Pseudomonas exotoxin-based therapies in clinical trials and advancements that enhance tumor-targeting capabilities while reducing immunogenicity.\n\nBy application, the therapy development segment accounted for the highest revenue in the global immunotoxins market in 2023, resulting from an increased focus on creating novel immunotoxin-based therapies. The biomedical research segment is projected to grow at the fastest CAGR during the forecast period, spurred by escalating interest in exploring immunotoxins for new therapeutic applications.\n\nBy end-user, the pharmaceutical and biotechnology companies segment represented the highest revenue-generating segment in the global immunotoxins market in 2023, attributed to robust R&D efforts, strong product pipelines, strategic partnerships, and the growing commercialization of innovative immunotoxin-based therapies. The academic and research institutes segment is expected to exhibit the fastest CAGR during the forecast period, driven by increased emphasis on fundamental research, heightened collaboration with pharmaceutical companies, access to government and private research funding, and advancements in the early-stage development of new immunotoxin therapies.\n\nNorth America is anticipated to have the highest revenue share during the forecast period owing to the presence of major pharmaceutical and biotechnology companies, advanced healthcare infrastructure, high investment in cancer research, and early adoption of innovative immunotoxin therapies. The Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of cancer, increasing healthcare expenditure, growing biotechnology and pharmaceutical sectors, expanding clinical trial activities, and improvements in healthcare infrastructure in countries such as China and India.\n\nKey players in the immunotoxins market include Amgen Inc., Eisai Co. Ltd., Genentech (Roche), AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Celltech Pharma Ltd., ImmunoGen Inc., BioNTech SE, Macrogenics Inc., Cellerant Therapeutics Inc., Iovance Biotherapeutics Inc., and Zymeworks Inc.\n[Output in JSON]\n",
  "response": "```json\n{\n  \"id\": \"T0\",\n  \"title\": \"Current Market Projection\",\n  \"description\": \"Global immunotoxins market projected to grow from USD 142.2M in 2023 to USD 344.7M by 2034, driven by rising malignancies, increased R&D, and strategic collaborations.\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"Breakthrough in Pseudomonas Exotoxin Engineering\",\n      \"date_range\": \"2024\",\n      \"description\": \"Major pharmaceutical company achieves significant reduction in immunogenicity of Pseudomonas exotoxin-based immunotoxins.\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"Accelerated Clinical Trials\",\n          \"description\": \"Enhanced immunotoxins receive expedited review status from regulatory bodies, shortening approval timelines.\",\n          \"children\": [\n            {\n              \"id\": \"T1A1.1.1\",\n              \"title\": \"Early Market Entry\",\n              \"description\": \"Companies launch new Pseudomonas exotoxin-based therapies earlier than competitors, capturing significant market share.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A1.1.1.1\",\n                  \"title\": \"Investor Opportunities\",\n                  \"description\": \"Investors increase holdings in key players, leading to stock price appreciation.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T2A1\",\n                      \"title\": \"Increased R&D Funding\",\n                      \"date_range\": \"2025-2027\",\n                      \"description\": \"Success spurs increased investment in R&D for next-generation immunotoxins across biotech sector.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T3A1\",\n                          \"title\": \"Diversification of Therapeutic Applications\",\n                          \"description\": \"Immunotoxins expand into treating rare cancers and other malignancies, broadening market scope.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T4A1\",\n                              \"title\": \"Global Market Expansion\",\n                              \"description\": \"Emerging markets like Asia Pacific adopt new therapies rapidly, driven by improved healthcare infrastructure.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T5A1\",\n                                  \"title\": \"Market Leadership Consolidated\",\n                                  \"description\": \"Leading companies establish dominance in global immunotoxins market, setting standards and pricing.\"\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T1A1.1.2\",\n              \"title\": \"Regulatory Hurdles\",\n              \"description\": \"Despite reduced immunogenicity, unforeseen side effects delay approvals in certain regions.\",\n              \"children\": [\n                {\n                  \"id\": \"T2A2\",\n                  \"title\": \"Enhanced Post-Market Surveillance\",\n                  \"date_range\": \"2026-2028\",\n                  \"description\": \"Regulators implement stringent monitoring for new therapies, increasing compliance costs.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T3A2\",\n                      \"title\": \"Shift to Personalized Medicine\",\n                      \"description\": \"Companies invest in personalized immunotoxin treatments to mitigate side effects, tailoring therapies to patient genetics.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T4A2\",\n                          \"title\": \"Niche Market Growth\",\n                          \"description\": \"Personalized therapies create new sub-segments within the immunotoxins market, attracting specialized investors.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Competitive Pressure Intensifies\",\n          \"description\": \"Other biotech firms replicate modifications, saturating the Pseudomonas exotoxin segment.\",\n          \"children\": [\n            {\n              \"id\": \"T2A3\",\n              \"title\": \"Price Wars Emerge\",\n              \"date_range\": \"2025-2029\",\n              \"description\": \"Increased competition drives down prices, impacting profit margins across the sector.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A3\",\n                  \"title\": \"Consolidations and Acquisitions\",\n                  \"description\": \"Larger firms acquire smaller biotech companies to consolidate technology and reduce competition.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A3\",\n                      \"title\": \"Market Fragmentation Reduced\",\n                      \"description\": \"Fewer, larger players dominate the market, leading to standardized pricing and wider distribution networks.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"Regulatory Changes Impacting Immunotoxins\",\n      \"date_range\": \"2024\",\n      \"description\": \"New regulations introduced to streamline approval processes for immunotoxin therapies while ensuring safety.\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Faster Approval Pathways\",\n          \"description\": \"Regulators establish accelerated pathways for promising immunotoxin therapies, reducing time to market.\",\n          \"children\": [\n            {\n              \"id\": \"T1A2.1.1\",\n              \"title\": \"Increased Market Entry\",\n              \"description\": \"More immunotoxin therapies enter the market, enhancing competition and innovation.\",\n              \"children\": [\n                {\n                  \"id\": \"T2A4\",\n                  \"title\": \"Diversified Product Portfolio\",\n                  \"date_range\": \"2025-2027\",\n                  \"description\": \"Companies expand their product lines to include a variety of immunotoxin-based treatments, catering to a broader patient base.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T3A4\",\n                      \"title\": \"Enhanced Patient Outcomes\",\n                      \"description\": \"Broader treatment options lead to improved patient outcomes and higher adoption rates.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T4A4\",\n                          \"title\": \"Global Health Impact\",\n                          \"description\": \"Widespread use of immunotoxin therapies contributes to reducing cancer mortality rates globally.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Increased Regulatory Scrutiny\",\n          \"description\": \"Enhanced safety and efficacy requirements lead to more rigorous clinical trials for immunotoxins.\",\n          \"children\": [\n            {\n              \"id\": \"T2A5\",\n              \"title\": \"Extended Development Timelines\",\n              \"date_range\": \"2025-2029\",\n              \"description\": \"Companies face longer development cycles, increasing costs and delaying market entry.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A5\",\n                  \"title\": \"Shift to Coalition R&D\",\n                  \"description\": \"Pharmaceutical firms collaborate more intensively to share R&D costs and meet regulatory standards.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A5\",\n                      \"title\": \"Strengthened Partnerships\",\n                      \"description\": \"Strategic alliances between biotech firms, academic institutes, and regulatory bodies enhance innovation and compliance.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A3\",\n      \"title\": \"Emergence of Novel Immunotoxin Technologies\",\n      \"date_range\": \"2024\",\n      \"description\": \"Innovative approaches such as bispecific immunotoxins and CAR-T cell linked toxins gain traction.\",\n      \"children\": [\n        {\n          \"id\": \"T1A3.1\",\n          \"title\": \"Adoption of Bispecific Immunotoxins\",\n          \"description\": \"Bispecific immunotoxins targeting multiple cancer markers demonstrate superior efficacy in clinical trials.\",\n          \"children\": [\n            {\n              \"id\": \"T1A3.1.1\",\n              \"title\": \"Broadening Therapeutic Applications\",\n              \"description\": \"Therapies are adapted for a wider range of cancers, including those previously hard-to-treat.\",\n              \"children\": [\n                {\n                  \"id\": \"T2A6\",\n                  \"title\": \"Increased Market Penetration\",\n                  \"date_range\": \"2025-2030\",\n                  \"description\": \"Higher efficacy leads to greater adoption by healthcare providers and inclusion in treatment guidelines.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T3A6\",\n                      \"title\": \"Revenue Growth for Innovators\",\n                      \"description\": \"Companies pioneering bispecific immunotoxins experience significant revenue increases, attracting further investment.\"\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T1A3.1.2\",\n              \"title\": \"Technological Integration\",\n              \"description\": \"Integration with AI-driven diagnostics enhances precision targeting of immunotoxin therapies.\",\n              \"children\": [\n                {\n                  \"id\": \"T2A7\",\n                  \"title\": \"Personalized Treatment Plans\",\n                  \"date_range\": \"2026-2032\",\n                  \"description\": \"AI enables customization of immunotoxin therapies based on individual patient profiles, improving outcomes and reducing side effects.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T3A7\",\n                      \"title\": \"Market Differentiation\",\n                      \"description\": \"Companies leveraging AI integrations differentiate their products, securing competitive advantages.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A3.2\",\n          \"title\": \"Advancements in CAR-T Linked Toxins\",\n          \"description\": \"CAR-T cell therapies enhanced with immunotoxins show promising results in clinical trials for solid tumors.\",\n          \"children\": [\n            {\n              \"id\": \"T2A8\",\n              \"title\": \"Expansion into Solid Tumors\",\n              \"description\": \"Successful treatments lead to expansion of immunotoxin applications beyond hematological malignancies.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A8\",\n                  \"title\": \"Increased Investment in CAR-T Technologies\",\n                  \"description\": \"Investor interest surges in CAR-T linked immunotoxins, driving funding into innovative startups and established firms.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A4\",\n      \"title\": \"Geopolitical and Economic Factors\",\n      \"date_range\": \"2024\",\n      \"description\": \"Global economic conditions and geopolitical dynamics influence the immunotoxins market trajectory.\",\n      \"children\": [\n        {\n          \"id\": \"T1A4.1\",\n          \"title\": \"Increased Healthcare Funding in Asia Pacific\",\n          \"description\": \"Governments in China and India ramp up healthcare spending, prioritizing cancer treatment advancements.\",\n          \"children\": [\n            {\n              \"id\": \"T2A9\",\n              \"title\": \"Regional Market Growth\",\n              \"description\": \"Asia Pacific becomes a major growth hub for immunotoxin therapies, fueled by local manufacturing and distribution capabilities.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A9\",\n                  \"title\": \"Strategic Partnerships\",\n                  \"description\": \"Western pharmaceutical companies establish joint ventures with Asian firms to penetrate the local markets effectively.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A4.2\",\n          \"title\": \"Global Trade Policies Impacting Biotech Supply Chains\",\n          \"description\": \"Trade tensions lead to disruptions in the supply of critical components for immunotoxin manufacturing.\",\n          \"children\": [\n            {\n              \"id\": \"T2A10\",\n              \"title\": \"Supply Chain Diversification\",\n              \"description\": \"Companies diversify their supply chains, sourcing materials from multiple regions to mitigate risks.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A10\",\n                  \"title\": \"Increased Operational Costs\",\n                  \"description\": \"Diversification strategies lead to higher operational expenditures, affecting profitability.\"\n                }\n              ]\n            },\n            {\n              \"id\": \"T2A11\",\n              \"title\": \"Local Production Initiatives\",\n              \"description\": \"Governments incentivize domestic production of immunotoxin components to reduce dependency on imports.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A11\",\n                  \"title\": \"Innovation in Manufacturing\",\n                  \"description\": \"Investment in local manufacturing spurs innovations in immunotoxin production technologies, enhancing efficiency.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A5\",\n      \"title\": \"Advancements in Biomedical Research\",\n      \"date_range\": \"2024\",\n      \"description\": \"Breakthroughs in understanding cancer biology and immunology drive the development of next-gen immunotoxins.\",\n      \"children\": [\n        {\n          \"id\": \"T1A5.1\",\n          \"title\": \"Discovery of New Targets\",\n          \"description\": \"Research identifies novel tumor-specific antigens, enabling the creation of highly selective immunotoxins.\",\n          \"children\": [\n            {\n              \"id\": \"T2A12\",\n              \"title\": \"Enhanced Therapeutic Efficacy\",\n              \"description\": \"Targeted immunotoxins demonstrate superior efficacy with minimal off-target effects in preclinical studies.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A12\",\n                  \"title\": \"Clinical Successes\",\n                  \"description\": \"Positive clinical trial outcomes lead to multiple immunotoxin approvals within a short timeframe.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A5.2\",\n          \"title\": \"Integration with Genomic Data\",\n          \"description\": \"Use of genomic data to personalize immunotoxin therapies based on individual genetic profiles.\",\n          \"children\": [\n            {\n              \"id\": \"T2A13\",\n              \"title\": \"Precision Medicine Growth\",\n              \"description\": \"Growth in precision medicine accelerates the adoption of tailored immunotoxin treatments, enhancing patient response rates.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A13\",\n                  \"title\": \"Data Partnerships\",\n                  \"description\": \"Pharma companies collaborate with genomic data firms to enhance therapy personalization.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A6\",\n      \"title\": \"Economic Downturn Impacting Healthcare Investments\",\n      \"date_range\": \"2024\",\n      \"description\": \"Global economic slowdown reduces available capital for R&D and commercialization of immunotoxin therapies.\",\n      \"children\": [\n        {\n          \"id\": \"T1A6.1\",\n          \"title\": \"Reduced R&D Budgets\",\n          \"description\": \"Pharmaceutical companies cut R&D spending, delaying the development of new immunotoxin therapies.\",\n          \"children\": [\n            {\n              \"id\": \"T2A14\",\n              \"title\": \"Focus on Core Products\",\n              \"description\": \"Companies prioritize already successful immunotoxin products over exploratory research, limiting innovation.\"\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A6.2\",\n          \"title\": \"Shift in Investment Strategies\",\n          \"description\": \"Investors become risk-averse, favoring established players and high-profit-margin therapies.\",\n          \"children\": [\n            {\n              \"id\": \"T2A15\",\n              \"title\": \"Funding Challenges for Startups\",\n              \"description\": \"Biotech startups focusing on novel immunotoxin approaches struggle to secure funding, slowing market diversification.\"\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n```",
  "processing_time": 66.49635004997253,
  "estimated_prompt_tokens": 2487,
  "response_tokens": 3336
}